Cresco Labs Inc. (CRLBF)
OTCQX OTCQX Primary 
XSTU 
3 Marijuana Stocks To Buy Or Sell In Today's Stock Market
Is now the best time to find top marijuana stocks to buy? Those who trade and invest in pot stocks know the challenges of making a profit. At one point in time when cannabis stocks would see a drop it was often followed by a big bounce and was able to sustain its momentum. Yet with speculation and volatility being a keen factor for investors should people buy or sell?
June 2024 Watchlist: Leading US Cannabis Stocks
The U.S. cannabis industry thrives, making top marijuana stocks a focal point for investors. Currently, the industry is valued at over $18 billion, with projections estimating it could reach $41 billion by 2025. The recent push for federal legalization has added momentum. Several states have moved towards legalizing recreational cannabis, further bolstering market growth. As more states adopt favorable laws, opportunities for cannabis companies expand. Investors are particularly interested in identifying top marijuana stocks that are in position for growth. Watching the performance of leading companies can offer insights into future market trends.
Top MSO Marijuana Stocks to Watch This Memorial Day Weekend
This Memorial Day weekend, investors are closely monitoring top U.S. MSO marijuana stocks. These multi-state operators are leading the charge in the rapidly growing cannabis industry. The U.S. cannabis market is projected to reach $41 billion by 2025, driven by increasing legalization and consumer demand. Recently, the U.S. House of Representatives passed the MORE Act, which aims to decriminalize marijuana at the federal level. This news has fueled optimism among investors, as federal legalization could significantly boost the market. However, it is crucial to use technical analysis to identify potential entry and exit points. Proper risk management strategies are essential to navigate the market's volatility.
Top Marijuana Stocks To Watch The 3rd Week Of May
Marijuana stocks could see strong trading this week. The reason is all the hype and news surrounding federal reform. Right now cannabis is still federally illegal. However, with the DEA's recent announcement to drop cannabis to class 3, the drug has the sector ramping up. Becuase of the volatility the sector encounters impactful news can change how marijuana stocks trade. For instance, when it's positive news on financials or laws it often leads to stronger trading for most marijuana stocks.
Q2 2024 EPS Estimates for Cresco Labs Inc. Raised by Echelon Wealth Partners (OTCMKTS:CRLBF)
Cresco Labs Inc. (OTCMKTS:CRLBF – Free Report) – Investment analysts at Echelon Wealth Partners upped their Q2 2024 earnings per share estimates for Cresco Labs in a note issued to investors on Wednesday, May 15th. Echelon Wealth Partners analyst A. Semple now anticipates that the company will post earnings per share of ($0.01) for the quarter, up from their prior forecast of ($0.02). Echelon Wealth Partners currently has a “Buy” rating on the stock. The consensus estimate for Cresco Labs’ current full-year earnings is ($0.05) per share. Echelon Wealth Partners also issued estimates for Cresco Labs’ Q3 2024 earnings at ($0.01) EPS, FY2024 earnings at ($0.02) EPS and FY2025 earnings at ($0.02) EPS. CRLBF has been the subject of a number of other reports. Needham & Company LLC restated a “hold” rating on shares of Cresco Labs in a research note on Thursday. Roth Mkm lifted their target price on Cresco Labs from $1.75 to $2.00 and gave the stock a “neutral” rating in a research note on Thursday, March 14th. Finally, Wedbush lifted their target price on Cresco Labs from $2.50 to $3.00 and gave the stock an “outperform” rating in a research note on Thursday. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, Cresco Labs has a consensus rating of “Moderate Buy” and an average target price of $2.63. Read Our Latest Stock Report on Cresco Labs Cresco Labs Stock Down 2.7 % Shares of Cresco Labs stock opened at $2.16 on Monday. The business’s 50 day simple moving average is $2.07 and its 200 day simple moving average is $1.84. Cresco Labs has a 52-week low of $1.00 and a 52-week high of $2.77. The firm has a market cap of $746.54 million, a PE ratio of -4.60 and a beta of 2.08. The company has a debt-to-equity ratio of 1.55, a quick ratio of 0.85 and a current ratio of 1.39. Cresco Labs (OTCMKTS:CRLBF – Get Free Report) last announced its earnings results on Wednesday, May 15th. The company reported ($0.02) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.02). Cresco Labs had a negative return on equity of 6.61% and a negative net margin of 20.32%. The business had revenue of $184.30 million for the quarter, compared to analyst estimates of $183.31 million. Cresco Labs Company Profile (Get Free Report) Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.
Q2 2024 Earnings Estimate for Cresco Labs Inc. (OTCMKTS:CRLBF) Issued By Wedbush
Cresco Labs Inc. (OTCMKTS:CRLBF – Free Report) – Equities research analysts at Wedbush lowered their Q2 2024 earnings per share estimates for Cresco Labs in a report released on Thursday, May 16th. Wedbush analyst G. Pascarelli now anticipates that the company will earn ($0.04) per share for the quarter, down from their prior estimate of ($0.03). Wedbush has a “Outperform” rating and a $3.00 price target on the stock. The consensus estimate for Cresco Labs’ current full-year earnings is ($0.05) per share. Wedbush also issued estimates for Cresco Labs’ Q3 2024 earnings at ($0.04) EPS, Q4 2024 earnings at ($0.04) EPS, FY2024 earnings at ($0.12) EPS, Q1 2025 earnings at ($0.03) EPS, Q2 2025 earnings at ($0.03) EPS, Q3 2025 earnings at ($0.03) EPS, Q4 2025 earnings at ($0.03) EPS and FY2025 earnings at ($0.11) EPS. Several other equities analysts have also weighed in on CRLBF. Needham & Company LLC reaffirmed a “hold” rating on shares of Cresco Labs in a research report on Thursday. Roth Mkm lifted their price target on shares of Cresco Labs from $1.75 to $2.00 and gave the company a “neutral” rating in a research report on Thursday, March 14th. Finally, Echelon Wealth Partners raised shares of Cresco Labs from a “hold” rating to a “buy” rating in a research report on Wednesday, March 13th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $2.63. Check Out Our Latest Stock Report on CRLBF Cresco Labs Price Performance Shares of CRLBF opened at $2.16 on Monday. The firm has a market cap of $746.54 million, a PE ratio of -4.60 and a beta of 2.08. The firm’s 50 day moving average price is $2.07 and its 200 day moving average price is $1.84. The company has a debt-to-equity ratio of 1.55, a quick ratio of 0.85 and a current ratio of 1.39. Cresco Labs has a twelve month low of $1.00 and a twelve month high of $2.77. Cresco Labs (OTCMKTS:CRLBF – Get Free Report) last issued its quarterly earnings data on Wednesday, May 15th. The company reported ($0.02) earnings per share for the quarter, meeting the consensus estimate of ($0.02). The firm had revenue of $184.30 million for the quarter, compared to analyst estimates of $183.31 million. Cresco Labs had a negative net margin of 20.32% and a negative return on equity of 6.61%. About Cresco Labs (Get Free Report) Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.
Q2 2024 EPS Estimates for Cresco Labs Inc. (OTCMKTS:CRLBF) Boosted by Alliance Global Partners
Cresco Labs Inc. (OTCMKTS:CRLBF – Free Report) – Analysts at Alliance Global Partners increased their Q2 2024 earnings per share (EPS) estimates for Cresco Labs in a research note issued on Wednesday, May 15th. Alliance Global Partners analyst A. Grey now forecasts that the company will earn ($0.01) per share for the quarter, up from their previous forecast of ($0.04). The consensus estimate for Cresco Labs’ current full-year earnings is ($0.05) per share. Alliance Global Partners also issued estimates for Cresco Labs’ Q3 2024 earnings at ($0.01) EPS, Q4 2024 earnings at ($0.01) EPS, FY2024 earnings at ($0.03) EPS and FY2025 earnings at ($0.02) EPS. Cresco Labs (OTCMKTS:CRLBF – Get Free Report) last posted its quarterly earnings data on Wednesday, May 15th. The company reported ($0.02) EPS for the quarter, meeting the consensus estimate of ($0.02). The business had revenue of $184.30 million for the quarter, compared to the consensus estimate of $183.31 million. Cresco Labs had a negative return on equity of 6.61% and a negative net margin of 20.32%. Several other equities research analysts also recently issued reports on CRLBF. Roth Mkm increased their target price on Cresco Labs from $1.75 to $2.00 and gave the stock a “neutral” rating in a research report on Thursday, March 14th. Wedbush increased their price objective on Cresco Labs from $2.50 to $3.00 and gave the stock an “outperform” rating in a research report on Thursday. Needham & Company LLC reissued a “hold” rating on shares of Cresco Labs in a research note on Thursday. Finally, Echelon Wealth Partners raised Cresco Labs from a “hold” rating to a “buy” rating in a research note on Wednesday, March 13th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $2.63. Read Our Latest Analysis on CRLBF Cresco Labs Trading Down 2.7 % OTCMKTS:CRLBF opened at $2.16 on Monday. The company has a market cap of $746.54 million, a P/E ratio of -4.60 and a beta of 2.08. The stock’s fifty day moving average price is $2.07 and its two-hundred day moving average price is $1.84. Cresco Labs has a 1 year low of $1.00 and a 1 year high of $2.77. The company has a debt-to-equity ratio of 1.55, a current ratio of 1.39 and a quick ratio of 0.85. Cresco Labs Company Profile (Get Free Report) Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand. Read More Five stocks we like better than Cresco Labs 3 Healthcare Dividend Stocks to Buy MarketBeat Week in Review – 5/13 – 5/17 How to Find Undervalued Stocks Take-Two Interactive Software Offers 2nd Chance for Investors What is a Low P/E Ratio and What Does it Tell Investors? Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook
